Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187794 | 0.86 | KDM4E (0.58) | ALDH1A1MAPTLMNAKDM4EL3MBTL1 | |
| SCHEMBL22412199 | 0.85 | CYP1A2 (0.50) | ALDH1A1MAPTLMNAKDM4EL3MBTL1 | |
| SCHEMBL29189923 | 0.84 | LCK (0.43) | ALDH1A1MAPTLMNAKDM4EPOLB | |
| SCHEMBL29150057 | 0.81 | NOTUM (0.40) | MAPTLMNAKDM4EPOLBTDP1 | |
| SCHEMBL4652551 | 0.75 | MYC (0.44) | ALDH1A1LMNAHTTSMN1; SMN2KMT2A | |
| SCHEMBL7226331 | 0.75 | KDM4E (0.47) | ALDH1A1MAPTKDM4EL3MBTL1NPC1 | |
| SCHEMBL14918993 | 0.75 | KDM4E (0.71) | ALDH1A1MAPTLMNAKDM4EL3MBTL1 | |
| SCHEMBL187354 | 0.75 | NPC1 (0.64) | ALDH1A1MAPTLMNAHPGDHTT | |
| SCHEMBL10562972 | 0.75 | MAPT (0.46) | ALDH1A1MAPTLMNAKDM4EL3MBTL1 | |
| SCHEMBL5117547 | 0.74 | CNR2 (0.40) | ALDH1A1MAPTL3MBTL1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024259241-A1 | 5-HT2A RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Transneural Therapeutics, Inc. (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024186626-A1 | AZA-BICYCLIC STING AGONIST IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-8829190-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2014-09-09 | — | — | US | disclosed |
| US-8829190-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2014-09-09 | — | — | US | disclosed |
| US-8829190-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2014-09-09 | — | — | US | disclosed |
| EP-2146989-B1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA AS (DK) | 2012-01-04 | — | — | EP | disclosed |
| EP-2146989-B1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA AS (DK) | 2012-01-04 | — | — | EP | disclosed |
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | FELDING JAKOB | 2010-05-06 | — | — | US | disclosed |
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | FELDING JAKOB | 2010-05-06 | — | — | US | disclosed |
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | FELDING JAKOB | 2010-05-06 | — | — | US | disclosed |
| US-6794404-B2 | BENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-09-21 | — | — | US | disclosed |
| EP-1411928-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-04-28 | — | — | EP | disclosed |
| US-20030236251-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-25 | — | — | US | disclosed |
| US-20030232816-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-18 | — | — | US | disclosed |
| EP-1301487-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-04-16 | — | — | EP | disclosed |
| WO-2003007945-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-01-30 | — | — | WO | disclosed |
| US-6479508-B1 | INHIBITOR OF RNA DEPENDENT RNA POLYMERASE ACTIVITY OF THE ENZYME NS5B ENCODED BY HEPATITIS C VIRUS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-11-12 | — | — | US | disclosed |
| US-6448281-B1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-09-10 | — | — | US | disclosed |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-05-30 | — | — | US | disclosed |
| WO-2002004425-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236251-A1 | Viral polymerase inhibitors | POLR2H, CTDSP1, POLR2E | ALDH1A1 3269/4885MAPT 3452/4885LMNA 481/4885 |
| US-20030232816-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | ALDH1A1 3670/4885MAPT 3559/4885LMNA 1560/4885 |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | HAVCR2, HCCS, ZC3HAV1 | ALDH1A1 2335/4885MAPT 4597/4885LMNA 2204/4885 |
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | PDE5A, PDE3A, PDE3B | ALDH1A1 760/4885MAPT 4191/4885LMNA 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.